A blog by Lynda Ware, Senior Fellow in General Practice with Cochrane UK, for non-medical readers, on treatment choices for women with heavy periods.
A shocking newspaper article
In February 2016 a newspaper headline caught my eye:
‘Nepal’s bleeding shame: menstruating women banished to cattle sheds’
The article described a centuries-old custom, still practised in Nepal, of confining women to a cowshed or outbuilding during their period. This ingrained cultural practice called chaupadi (which translates as ‘untouchable being’) considers menstrual loss to be ‘impure’ and places severe restrictions on what women can eat, where they can go and with whom they can interact. The damage to women – both physical and psychological – is huge and efforts are being made to outlaw the behaviour.
A month before this piece was written, a Cochrane review was published looking at Surgery versus medical therapy for heavy menstrual bleeding. It occurred to me that this highlighted the very different world in which we live.
How heavy is heavy?
Now here’s the rub. What constitutes an unacceptably heavy period is very subjective. Medical wisdom defines heavy menstrual bleeding (or menorrhagia, to give it its medical name) as a loss of 80ml or more per menstrual cycle. When menstrual blood is measured (and it can be!) only about half of the women attending gynaecology clinics with a complaint of heavy periods are losing 80ml or more. A survey of menstruating women conducted in 2004 in the UK found that the self-reported incidence of menorrhagia was 25%. It is estimated that 5% of otherwise healthy women consult their GP complaining of heavy periods.
Heavy menstrual bleeding can significantly impair quality of life. It can of course cause anaemia and incurs a not insubstantial financial cost in terms of sanitary items and lost days at work if severe.
What is available to help?
A number of medical and surgical options are available to help lessen menstrual bleeding.
Initial treatment for menorrhagia, as recommended by NICE and the Royal College of Gynaecologists and Obstetricians, is usually medical and includes:
Levonorgesterel-intrauterine device (LNG-IUS). This is inserted into the womb and lasts for up to five years. It releases a low level of levonorgestrel (a progesterogenic hormone) which has the effect of suppressing the lining of the womb (endometrium). It has been reported to reduce menstrual loss by 94% in three months. It has the added advantage of being a highly effective contraceptive. However, it commonly causes irregular bleeding in the first few months of use and some women experience hormonal side effects such as weight gain and bloating.
Anti-fibrinolytic drugs such as tranexamic acid inhibit the breakdown of blood clots and can reduce bleeding by 40-50%. They are taken during menstruation and are usually well tolerated but can cause mild nausea and diarrhoea. Historically there has been some concern that they may increase the risk of venous thromboembolic disease (ie blood clots in the legs or lungs).
Non-steroidal anti-inflammatory drugs (NSAIDs) such as mefenamic acid and naproxen can reduce bleeding by 33-55%. These drugs are also taken just at the time of menstruation. Side effects such as indigestion and diarrhoea are less likely to cause problems since the NSAIDs are only taken for a few days each cycle.
Progestogens such as norethisterone and medroxyprogesterone acetate are taken on a cyclical basis. They can be effective at reducing blood loss and at helping to regulate the menstrual cycle. Long term they are often unacceptable because of their side effects such as bloating, headache, breast tenderness and breakthrough bleeding. The contraceptive injection (eg Depo-Provera) may stop periods altogether but it is not licensed as a treatment for menorrhagia.
The combined oral contraceptive pill can often diminish menstrual loss although there is little randomized evidence supporting this.
Danazol is a synthetic hormone and it is highly effective at reducing menstrual loss. However side effects such as weight gain, headache, nausea, tiredness and acne are common and can be severe.
These include hysterectomy and conservative surgery in the form of endometrial resection or ablation.
Hysterectomy requires a general anaesthetic and a lengthy postoperative recovery period. It can be associated with postoperative complications, some of which may be serious.
Endometrial resection or ablation involves removing the lining of the womb by cutting it away or by destroying it, for example by contact with heat, cold or microwaves. These techniques are less invasive than hysterectomy and involve a shorter hospital stay, quicker recovery and fewer postoperative complications. Menstrual bleeding does not always cease completely and contraception should still be used. It has been reported that up to a third of women go on to have a hysterectomy after a previous ablation procedure.
What does the Cochrane review look at?
This review from the Cochrane Gynaecology and Fertility Group set out to compare the effectiveness, safety and acceptability of surgery versus medical therapy for heavy menstrual bleeding. It was published in January 2016 as an update to the original from 2010. Fifteen trials were included involving 1289 women, aged 30-50, all of whom had sought help for heavy periods.
How good was the evidence?
The quality of the evidence varied from very low to moderate.
Some of the findings from the long-term studies were difficult to interpret since many women randomized to medical treatments went on to have surgery.
So what did the review find?
Surgery, especially hysterectomy, reduced menstrual loss more than medical treatment at one year. Oral medication did, however, suit a minority of women long term. There was no conclusive evidence of a difference in satisfaction between surgery and LNG-IUS. A high proportion of women initially treated with oral medication, conservative surgery or the LNG-IUS went on to require further intervention. Hysterectomy, though the definitive treatment, was sometimes associated with serious side effects. Conservative surgery and the LNG-IUS appeared to be safe, acceptable and effective.
How might further research contribute?
A multi-centre trial is under way in the Netherlands looking at an up-to-date method of endometrial ablation and comparing it to the LNG-IUS.
It has always seemed to me to be a design flaw in the grand scheme of things that women are destined to have periods for nearly forty years of their lives. Not very 21st century – surely we can do better?
For many the monthly cycle is a nuisance; for others it is a regular life changer causing disruption to everyday life. In Nepal it can mean rejection by society, sometimes with disastrous consequences. This review gives an insight into the choices available to some women.
Since writing this blog a further Cochrane Review has been published looking specifically at the role of antifibrinolytics for heavy menstrual bleeding. The updated review studied comparisons of antifibrinolytic drugs, mainly tranexamic acid, versus placebo/no treatment, the LGN-IUS, progestogens, and NSAIDs.
The authors concluded that antifibrinolytic treatment is probably effective in reducing menstrual blood loss when compared to placebo (moderate certainty evidence). What this means is that if 11% of women improve without treatment, 43% to 63% of women on antifibrinolytics will do so. There is low certainty evidence that antifibrinolytics are more effective than NSAIDs or cyclical progestogens. However, the most effective treatment is probably the LGN-IUS (moderate certainty evidence). The comparison with antifibrinolytics shows 85% of women improving with the LGN-IUS compared to 20% to 65% taking tranexamic acid.
There are insufficient data to determine whether antifibrinolytics are associated with an increase in adverse events, in particular venous thromboembolism.
Bryant‐Smith AC, Lethaby A, Farquhar C, Hickey M. Antifibrinolytics for heavy menstrual bleeding. Cochrane Database of Systematic Reviews 2018, Issue 4. Art. No.: CD000249. DOI: 10.1002/14651858.CD000249.pub2.
Surgery versus medical therapy for heavy menstrual bleeding. Cochrane Database of Systematic Reviews 2016, Issue 1. Art. No.: CD003855. DOI: 10.1002/14651858.CD003855.pub3., , .
National Institute for Health and Care Excellence. Heavy menstrual bleeding: assessment and management. London: National Institute for Health and Care Excellence; 2018. (NICE NG88). [Issued March 2018; last updated November 2018]. Available from:https://www.nice.org.uk/guidance/ng88
National Institute for Health and Care Excellence. Heavy menstrual bleeding. London: National Institute for Health and Care Excellence; 2018. (NICE Quality Standard: QS47). [Issued September 2013; last updated March 2018]. Available from: https://www.nice.org.uk/guidance/qs47
NICE Press Release:
National Institute for Health and Care Excellence. “10,000 more women to be offered test to identify the cause of heavy periods”, NICE, News and features, 14 March 2018. Web. 23 January 2019. https://www.nice.org.uk/news/article/10-000-more-women-to-be-offered-test-to-identify-the-cause-of-heavy-periods
Page last updated 23 January 2019